You just read:

CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis

News provided by

CTI BioPharma Corp.

Jul 18, 2019, 07:00 ET